혈액 악성 종양 시장 보고서 : 종류별, 치료법별, 최종사용자별, 지역별(2026-2034년)

The global hematologic malignancies market size reached USD 70.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 133.9 Billion by 2034, exhibiting a growth rate (CAGR) of 7.25% during 2026-2034. Growing prevalence of blood cancer, increasing adoption of targeted therapies and immunotherapies tailored to genetic profiles, and expansion of biopharmaceutical pipelines focusing on novel treatments for hematologic cancers are some of the key factors driving the growth of the market.

Hematologic Malignancies Market Trends:

Rising Prevalence of Blood Cancer

Escalating incidences of blood cancer and a growing emphasis on the development of new treatments are primarily driving the growth in the hematologic malignancies market. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America. Thus, the high incidence of leukemia worldwide is expected to drive the hematologic malignancies market growth. Similarly, according to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. According to the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, a prominent rise in blood cancer cases in the market is expected to propel the hematologic malignancies market value over the forecasted period.

Growing Number of Product Launches, Partnerships, and Collaborations

Numerous companies are implementing diverse strategic initiatives such as launching new products, forming partnerships, fostering collaborations, and engaging in mergers and acquisitions to enhance their market presence. This, in turn, is positively impacting the hematologic malignancies market outlook. For instance, in October 2020, AstraZeneca Pharma India announced the launch of Acalabrutinib 100 mg capsules, which are used for the treatment of various types of leukemias (leukemia (CLL) and small lymphocytic lymphoma) under the brand name Calquence. Similarly, in January 2024, Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets. Such innovations are projected to augment the hematologic malignancies market demand in the coming years.

Increasing Product Approvals

Various concerned regulatory authorities are increasingly approving hematologic malignancies drugs, which is creating a positive outlook for the overall market. For instance, in September 2020, the US FDA approved Bristol Myers Squibb's azacytidine (Onureg) 300 mg tablets, CC-486, to continue treating adult patients with acute myeloid leukemia. Similarly, in March 2021, Sanofi SA received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. In line with this, in February 2021, TG Therapeutics Inc. received the US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL). Significant growth in number of approved drugs for treating blood cancer is propelling the hematologic malignancies market value.

Global Hematologic Malignancies Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global hematologic malignancies market report, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on type, therapy, and end user.

Breakup by Type:

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

The hematologic malignancies market report has provided a detailed breakup and analysis of the market based on the type. This includes leukemia, lymphoma, multiple myeloma, and others.

Leukemia is a type of hematologic malignancy, also known as blood cancer, that originates in the bone marrow and affects the production of blood cells. The rising cases of leukemia across the globe are bolstering the hematologic malignancies market share. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America.

Furthermore, the significant rise in the multiple myeloma market is a clear indication of the need for increased research and development. For instance, according to the Global Cancer Observatory, in 2020, nearly 35,318 cases of multiple myeloma were reported in the North American region. This rise in multiple myeloma cases underscores the importance of your work and is positively influencing the hematologic malignancies market price trends.

Breakup by Therapy:

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Stem Cell Transplantation
• Others

As per the hematologic malignancies market overview, for most types of blood cancers, chemotherapy is the common treatment. The large patient pool and the increasing incidence of blood cancers are the major drivers augmenting the need for chemotherapy. For instance, in June 2019, the United States Food and Drug Administration granted approval to Polivy to be used in combination with the chemotherapy drug bendamustine and rituximab to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

Breakup by End User:

• Hospitals
• Diagnostics Centers
• Research Centers
• Others

The hematologic malignancies market research report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostics centers, research centers, and others.

Hospitals are primary end users in the hematologic malignancies market, providing diagnosis, treatment, and ongoing care for patients with blood cancers, such as leukemia, lymphoma, and myeloma. They offer a range of specialized services, including chemotherapy, radiation therapy, stem cell transplantation, and supportive care. Hospitals also serve as centers for clinical trials and research, driving advancements in treatment options and patient outcomes.

Diagnostics centers are essential for early detection and monitoring of hematologic malignancies through a variety of tests, including blood tests, bone marrow biopsy, imaging studies, and genetic testing. These centers provide accurate diagnostic services, enabling healthcare providers to initiate timely treatment strategies. Diagnostics centers often collaborate closely with hospitals and oncology clinics to ensure comprehensive patient care and management throughout the treatment journey.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.

Besides this, hematologic malignancies market statistics indicates that the presence of key players, the high prevalence of blood cancer patients, established healthcare infrastructure, and the availability of branded drugs in North America and Asia Pacific countries are positively impacting the hematologic malignancies industry. According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. As per the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, the increasing number of blood cancer cases in the region is a major driving factor for the growth of the market. Besides this, hematologic malignancies market forecast indicates that beneficial government initiatives and an increase in the number of research partnerships are further contributing to the market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly US$ 17 Million in research grants to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the detailed profiles of the following key players:

• AbbVie Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co. Inc
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report:

• How big is the hematologic malignancies market?
• How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global hematologic malignancies market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the therapy?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global hematologic malignancies market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Hematologic Malignancies Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Leukemia
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Lymphoma
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Multiple Myeloma
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Therapy

• 7.1 Chemotherapy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Radiotherapy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunotherapy
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Stem Cell Transplantation
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diagnostics Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Research Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AbbVie Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AstraZeneca plc
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Bristol-Myers Squibb Company
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Eli Lilly and Company
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 F. Hoffmann-La Roche Ltd
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 GlaxoSmithKline plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Johnson & Johnson
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Merck & Co. Inc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Novartis AG
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Pfizer Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Sanofi S.A.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Takeda Pharmaceutical Company Limited
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis